Logo image of DRUG

BRIGHT MINDS BIOSCIENCES INC (DRUG) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:DRUG - CA10919W4056 - Common Stock

80.01 USD
-3.45 (-4.13%)
Last: 1/5/2026, 8:26:11 PM
105.99 USD
+25.98 (+32.47%)
Pre-Market: 1/6/2026, 8:31:59 AM
Fundamental Rating

2

Taking everything into account, DRUG scores 2 out of 10 in our fundamental rating. DRUG was compared to 530 industry peers in the Biotechnology industry. DRUG scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. DRUG is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DRUG has reported negative net income.
DRUG had a negative operating cash flow in the past year.
DRUG had negative earnings in each of the past 5 years.
In the past 5 years DRUG always reported negative operating cash flow.
DRUG Yearly Net Income VS EBIT VS OCF VS FCFDRUG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M

1.2 Ratios

The Return On Assets of DRUG (-16.99%) is better than 78.30% of its industry peers.
DRUG has a Return On Equity of -17.20%. This is amongst the best in the industry. DRUG outperforms 84.72% of its industry peers.
Industry RankSector Rank
ROA -16.99%
ROE -17.2%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DRUG Yearly ROA, ROE, ROICDRUG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DRUG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DRUG Yearly Profit, Operating, Gross MarginsDRUG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 5 years ago, DRUG has more shares outstanding
DRUG Yearly Shares OutstandingDRUG Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2024 1M 2M 3M 4M
DRUG Yearly Total Debt VS Total AssetsDRUG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2024 5M 10M 15M 20M

2.2 Solvency

DRUG has an Altman-Z score of 766.11. This indicates that DRUG is financially healthy and has little risk of bankruptcy at the moment.
DRUG's Altman-Z score of 766.11 is amongst the best of the industry. DRUG outperforms 100.00% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that DRUG is not too dependend on debt financing.
DRUG's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. DRUG outperforms 51.13% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 766.11
ROIC/WACCN/A
WACCN/A
DRUG Yearly LT Debt VS Equity VS FCFDRUG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

A Current Ratio of 86.56 indicates that DRUG has no problem at all paying its short term obligations.
DRUG has a Current ratio of 86.56. This is amongst the best in the industry. DRUG outperforms 100.00% of its industry peers.
DRUG has a Quick Ratio of 86.56. This indicates that DRUG is financially healthy and has no problem in meeting its short term obligations.
DRUG has a better Quick ratio (86.56) than 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 86.56
Quick Ratio 86.56
DRUG Yearly Current Assets VS Current LiabilitesDRUG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2024 5M 10M 15M 20M

More info and screens

0

3. Growth

3.1 Past

DRUG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -41.94%.
EPS 1Y (TTM)-41.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1580%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DRUG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DRUG Price Earnings VS Forward Price EarningsDRUG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DRUG Per share dataDRUG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

DRUG does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

BRIGHT MINDS BIOSCIENCES INC

NASDAQ:DRUG (1/5/2026, 8:26:11 PM)

Premarket: 105.99 +25.98 (+32.47%)

80.01

-3.45 (-4.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11
Earnings (Next)N/A N/A
Inst Owners73.1%
Inst Owner Change0%
Ins Owners14.52%
Ins Owner ChangeN/A
Market Cap623.28M
Revenue(TTM)N/A
Net Income(TTM)-8.92M
Analysts85.71
Price TargetN/A
Short Float %5.36%
Short Ratio1.79
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 16.47
P/tB 16.47
EV/EBITDA N/A
EPS(TTM)-0.96
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.74
FCFYN/A
OCF(TTM)-0.74
OCFYN/A
SpS0
BVpS4.86
TBVpS4.86
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -16.99%
ROE -17.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 86.56
Quick Ratio 86.56
Altman-Z 766.11
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-41.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1580%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-151.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.86%
OCF growth 3YN/A
OCF growth 5YN/A

BRIGHT MINDS BIOSCIENCES INC / DRUG FAQ

What is the ChartMill fundamental rating of BRIGHT MINDS BIOSCIENCES INC (DRUG) stock?

ChartMill assigns a fundamental rating of 2 / 10 to DRUG.


What is the valuation status of BRIGHT MINDS BIOSCIENCES INC (DRUG) stock?

ChartMill assigns a valuation rating of 0 / 10 to BRIGHT MINDS BIOSCIENCES INC (DRUG). This can be considered as Overvalued.


How profitable is BRIGHT MINDS BIOSCIENCES INC (DRUG) stock?

BRIGHT MINDS BIOSCIENCES INC (DRUG) has a profitability rating of 1 / 10.


How financially healthy is BRIGHT MINDS BIOSCIENCES INC?

The financial health rating of BRIGHT MINDS BIOSCIENCES INC (DRUG) is 5 / 10.